Pricing Log in Create free account
Friday 6 November 2026 Export AZN’s income statement to Excel — free account

AstraZeneca PLC

AZN Healthcare Drug Manufacturers General

AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.

Revenue
+6.70%
EPS
+22.5%
Free cash flow
+1.99%
Total debt
+1.75%

Quarter to September 2026, against a year earlier

187.20 1.81 −0.96%
Market cap
$289.8B
P/E
26.3×
Fwd P/E
24.5×
Dividend yield
1.71%
F-score
9/9
Altman Z
3.52
Beneish M
−2.51
Dividend safety
54/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

AstraZeneca PLC (AZN) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, AstraZeneca PLC (AZN) trades at a EV/EBITDA of 14.8×. Over the past ten years it has ranged from 10.6× (January 2017) to 34.5× (March 2015); the current reading is higher than 25% of that period. That is in line with the Drug Manufacturers General industry median of 14.8× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 15.1× 12.04%
FY2024 13.5× (19.49%)
FY2023 16.7× (33.69%)
FY2022 25.2× 2.01%
FY2021 24.7× 42.64%
FY2020 17.3× (18.78%)
FY2019 21.3× 39.27%
FY2018 15.3× 2.81%
FY2017 14.9× 33.60%
FY2016 11.2× (17.34%)

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 12.9× (17.58%)
Jun 2026 15.7× (4.35%)
Mar 2026 16.4× 8.60%
Dec 2025 15.1× 14.74%
43 more quarters

Against its own ten years

Low 10.6× High 34.5×
Ten-year median 16.7×
Current reading's percentile 25

EV/EBITDA against peers

Company EV/EBITDA
NVO Novo Nordisk A/S compare 7.3×
PFE Pfizer Inc. compare 10.9×
BMY Bristol Myers Squibb Company compare 11.3×
AZN AstraZeneca PLC 14.8×
NVS Novartis AG compare 15.6×
AMGN Amgen Inc. compare 17.6×
ABBV AbbVie Inc. compare 20.1×
MRK Merck & Co., Inc. compare 29.7×
GILD Gilead Sciences, Inc. compare 505×
Drug Manufacturers General industry median 14.8×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on AZN